The CCNT2 antibody targets cyclin T2. a regulatory protein encoded by the *CCNT2* gene, which belongs to the cyclin family. Cyclins are critical for cell cycle progression and transcriptional regulation by binding to cyclin-dependent kinases (CDKs). CCNT2 specifically partners with CDK9 to form the positive transcription elongation factor b (P-TEFb) complex. This complex phosphorylates RNA polymerase II, enabling transcriptional elongation of target genes, including those involved in stress responses, differentiation, and viral replication (e.g., HIV-1).
CCNT2 is expressed in various tissues and plays roles beyond the cell cycle, such as modulating gene expression in immune cells and neurons. Antibodies against CCNT2 are essential tools for studying its expression, localization, and interactions in both physiological and pathological contexts. They are widely used in techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP). Research involving CCNT2 antibodies has shed light on its dysregulation in cancers, neurodegenerative diseases, and viral infections, highlighting its potential as a therapeutic target. Commercial CCNT2 antibodies are typically validated for specificity and sensitivity across species, including human and mouse models.